- Report
- October 2025
- 472 Pages
Global
From €5233EUR$5,850USD£4,603GBP
- Report
- February 2025
- 200 Pages
Global
From €4016EUR$4,490USD£3,533GBP
- Report
- September 2025
- 137 Pages
Global
From €2280EUR$2,549USD£2,006GBP
€2682EUR$2,999USD£2,360GBP
- Report
- June 2025
- 400 Pages
Global
From €4427EUR$4,949USD£3,894GBP
- Report
- June 2025
- 269 Pages
Global
From €3421EUR$3,825USD£3,009GBP
€4025EUR$4,500USD£3,541GBP
- Report
- October 2024
- 120 Pages
Global
From €5322EUR$5,950USD£4,681GBP
- Report
- May 2024
- 200 Pages
Global
From €3712EUR$4,150USD£3,265GBP
- Report
- February 2024
- 171 Pages
Global
From €4025EUR$4,500USD£3,541GBP
- Report
- December 2022
- 142 Pages
Global
From €3155EUR$3,528USD£2,775GBP
€3712EUR$4,150USD£3,265GBP
- Report
- August 2023
- 99 Pages
Global
From €3500EUR$4,192USD£3,186GBP
The ADME Toxicology Testing market is a subset of the Drug Discovery market, which focuses on the development of new drugs. ADME stands for Absorption, Distribution, Metabolism, and Excretion, and Toxicology Testing is the process of assessing the safety of a drug. This testing is conducted to ensure that the drug is safe for human use and does not cause any adverse effects. The testing process involves the use of in vitro and in vivo models, as well as the use of biomarkers to measure the drug’s toxicity. The results of the testing are then used to determine the safety of the drug and its potential for use in clinical trials.
Some of the companies in the ADME Toxicology Testing market include Charles River Laboratories, Eurofins Scientific, WuXi AppTec, SGS, and Covance. Show Less Read more
